Ekso Bionics Holdings, Inc. cash flow to debt ratio of -254.11% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ekso Bionics Holdings, Inc.'s free cash flow has decreased 21.31% from $-9.88M last year to $-11.99M, signaling decreasing performance

Ekso Bionics Holdings, Inc.'s debt to equity ratio is 0.75, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Ekso Bionics Holdings, Inc.'s debt has increased relative to shareholder equity from 0.47 last year to 0.75 today, signaling weakened financials

Ekso Bionics Holdings, Inc. has negative EBITDA, making leverage ratio unreliable

Ekso Bionics Holdings, Inc.'s interest coverage ratio is -22.47, which means that the company struggles to meet interest obligations, signaling financial risk.

Ekso Bionics Holdings, Inc.'s profit margin has decreased (114.62%) in the last year from -63.21% to -135.66%, signaling decreasing performance

Ekso Bionics Holdings, Inc.'s short-term assets of $14.05M exceed its short-term liabilities of $8.64M

Ekso Bionics Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ekso Bionics Holdings, Inc.'s return on equity of -177.40%, is lower than 15.00%, indicating bad performance

Ekso Bionics Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ekso Bionics Holdings, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Ekso Bionics Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ekso Bionics Holdings, Inc. has negative free cash flow, indicating cash burn

Ekso Bionics Holdings, Inc.'s yearly earnings has decreased 3.22% since last year from $-11.33M to $-11.70M, signaling decreasing performance

Ekso Bionics Holdings, Inc.'s yearly revenue has decreased -28.60% since last year from $17.93M to $12.80M, signaling decreasing performance

ROIC -108.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Ekso Bionics Holdings, Inc.'s 3-year revenue CAGR of -0.29% is negative, indicating declining revenue over the past 3 years

Ekso Bionics Holdings, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Ekso Bionics Holdings, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Ekso Bionics Holdings, Inc. has insufficient data to evaluate this check.

Ekso Bionics Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ekso Bionics Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Ekso Bionics Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ekso Bionics Holdings, Inc. has insufficient data to evaluate this check.

Ekso Bionics Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ekso Bionics Holdings, Inc. has a price-to-book ratio of 13.78x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Ekso Bionics Holdings, Inc. has a price-to-sales ratio of 4.66x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue